Everything about whether to start, dose, or stop a GLP-1 belongs with your prescribing physician; this page is the coaching side, which is where these medications quietly go wrong. Rapid weight loss on a crushed appetite takes muscle along with fat unless two floors are held: a hard daily protein number (difficult precisely because the drug kills hunger, so protein gets scheduled, not left to appetite) and three to four strength sessions a week, because unloaded muscle in a steep deficit is muscle the body lets go. The off-ramp matters as much as the loss: appetite returns after the last dose, and the man who spent the medicated months building training habit, muscle, and protein routine keeps the result. The man who only lost weight starts over, lighter and weaker.
The lane, stated plainly
Whether a GLP-1 belongs in your life is a conversation for a physician: yours, or for clients, the program physician by written handoff. Nothing on this page is medication advice. But most of what determines whether a GLP-1 ends well is not medical at all; it is the unglamorous coaching territory of protein, lifting, and what happens after the last injection, and that territory is being badly neglected in the middle of the biggest pharmaceutical weight-loss wave in history.
The problem the scale hides
Rapid loss on a crushed appetite is indiscriminate. When protein collapses and the muscle is not being loaded, the body sheds lean mass along with fat, and the scale applauds the whole way down. The result walks into our strategy calls regularly: a man who lost thirty pounds and looks and feels worse, “too skinny,” weaker, and now facing maintenance with less of the exact tissue that handles glucose and drives resting burn. He did not fail; nobody held the floors.
The two floors
Protein, scheduled rather than felt. The medication removes hunger, and with it every natural reminder to eat protein. So the number gets planned like a meeting: a hard daily target, anchored first at each meal, tracked honestly, even on days when eating is a chore. This is the single hardest behavior on a GLP-1 and the single most protective.
Strength training, three to four days a week. Loaded muscle is muscle the body keeps. Compound movements, joint-friendly, progressed by reps, on the same schedule whether the scale is generous that week or not. Cardio does not do this job; only load does.
And underneath both: a body-composition measure, not a bathroom scale. A smart scale trend or periodic DEXA shows lean mass leaving within weeks, while the scale alone will hide it until the end.
The off-ramp is the actual test
Every medicated loss ends, by plan or by circumstance, and the stopping itself is a physician conversation. What a coach can say with confidence: the off-ramp is built during the loss, not at it. The medicated months are a window in which the eating side is chemically easy; the men who spend that window building the training habit, the protein routine, and actual muscle walk off the medication into a maintenance life that already exists. The men who spend it only losing weight walk off into the same appetite they started with, minus the muscle. Same drug, opposite outcomes, and the difference was never the prescription.
What the research says
- A real share of the loss is lean mass. Across 28 trials that measured body composition by DXA, 20 to 40% of the weight lost on GLP-1-based drugs was fat-free mass, compared with under 25% for most diets (Dubin et al., Diabetes, Obesity and Metabolism, 2024).
- The weight comes back after stopping. One year after stopping semaglutide, participants regained two-thirds of the weight they had lost, and their cardiometabolic gains moved back toward baseline (Wilding et al., Diabetes, Obesity and Metabolism, 2022).
- The randomized trial says the same. Participants switched to placebo after 20 weeks regained 6.9% of body weight over the next 48 weeks, while those who continued lost a further 7.9% (Rubino et al., JAMA, 2021).
- Medical societies name the same floors. A joint advisory from four obesity and nutrition societies names muscle and bone loss as a challenge of GLP-1 therapy and calls for resistance training, appropriate diet, and a body-composition baseline (Mozaffarian et al., American Journal of Clinical Nutrition, 2025).
Where the coaching lane ends
Starting, dosing, side effects, stopping, and everything else pharmaceutical: physician, every time. At Executive Health Edge that handoff is written and structural, and the 75+ biomarker panel at months 0, 6, and 12 grades the whole story, because fasting insulin, lipids, and body composition, not the scale, say whether the year actually worked.
This page is coaching information, not medical advice. Questions about medication, hormones, or peptides go to the program physician.